Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Scientists at St. Jude Children's Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed ...
A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international Phase I/II clinical trial led ...
River Brennan couldn't wait to start middle school, but after his lymphoma diagnosis, doctors said he would miss the entire year River Brennan was diagnosed with T-cell lymphoblastic lymphoma the ...
ST. LOUIS, Mo., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological ...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that arises from the malignant transformation of T-cell progenitors. This disease is most commonly diagnosed in children, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results